You are here

Michael DeRan


Chen B, Zheng B, DeRan M, et al. ZDHHC7-mediated S-palmitoylation of Scribble regulates cell polarity. Nat Chem Biol. 2016;12(9):686–693.

DeRan M, Yang J, Shen C-H et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 2014;9(2):495–503.

Chen EY, DeRan MT, Ignatius MS et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/Beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U.S.A. 2014;111(14):5349–5354.

Michael DeRan, Ph.D.

Michael DeRan is a research scientist working under the direction of Bridget Wagner in the Center for the Science of Therapeutics (CSofT) Chemical Biology Program at the Broad Institute of MIT and Harvard. Since joining the Broad Institute in 2016, his work has focused on developing therapeutics for type 2 diabetes.

Before joining the Broad Institute, DeRan completed his postdoctoral work at Massachusetts General Hospital in the laboratory of Xu Wu. His work focused on using chemical biological approaches to explore disease-relevant signaling pathways. This work resulted in the discovery of novel regulators of the tumor suppressor Hippo-YAP pathway as well as regulators of cancer stem cell differentiation in embryonal rhabdomyosarcoma. Prior to his postdoctoral training, DeRan earned his Ph.D. in biochemistry from the University of Rochester in the laboratory of Jiyong Zhao. His graduate work focused on cell cycle regulation and DNA double-strand break repair. He also holds a B.S. in biochemistry from Saint Bonaventure University.

Contact Michael DeRan at

December 2016